31 results on atopic dermatitis
To collect prospective clinical and molecular data on the phenotypical characteristics of patients with atopic dermatitis (AD) receiving standard care targeted systemic treatment.
PrimaryPart 3 - Repeated doses in atopic dermatitis (AD) patients - PDY16891* To evaluate the safety and tolerability of SAR443726 after repeated SC doses in adult participants with moderate-to-severe ADSecondaryPart 3 - Repeated doses in AD…
Primary objective:Assess the efficacy of rilzabrutinib in participants with atopic dermatitis (AD)Secondary objectives: * Assess the efficacy of rilzabrutinib at different time points* Assess the safety of rilzabrutinib
Primary:To provide access to abrocitinib to adolescent and adult patients with or without background topical therapy who have inadequate treatment options due to inadequate response or intolerance to available approved medicated topical and systemic…
This Phase 1, First in Human study is designed to assess the safety and systemic exposure (pharmacokinetics (PK)) of single dose (Part A,B) and multiple dose (thrice daily) for 14 days (Part C) topical M528101 Liquid 0.3% in healthy volunteers (Part…
To evaluate the efficacy of lebrikizumab compared with placebo in patients not adequately controlled with cyclosporine or for whom cyclosporine is not medically advisable up to Week 16
Risk factors for poor growth in food allergic children are ongoing inflammation caused by atopic dermatitis, food allergy and possibly low energy and nutrient intakes.
This is a FIH study for M528101. We expect that the compound is safe and tolerable.
The synbiotic composition of the diet of the mother is reflected in the synbiotic composition of breast milk and sustains the prevention or promotion of the development of allergic disease in the infant.
Primary - To evaluate disease-related characteristics and biomarkers in patients with mycosis fungoides compared to healthy volunteers; Secondary - To evaluate intra- and inter-patient variability of the selected biomarkers; - To evaluate biomarkers…
Primary- To evaluate disease-related characteristics and biomarkers in patients with mycosis fungoides compared to healthy volunteers; Secondary- To evaluate the variability of the selected biomarkers between patients and within patients over time…
Primary Objective:Our main objective is to analyse if the microbiota composition of the affected skin is different from the non-affected skin in XRI and ARCI. Secondary Objectives:(1) To investigate the composition of the skin microbiota of patients…
The overall aim of this study is to evaluate objectively measured disease related characteristics in patients with different vulvar conditions compared to healthy volunteers.
Primary objective:To evaluate the long-term safety of an as-needed treatment with twice-daily applications of delgocitinib cream 20 mg/g.Secondary objective:To evaluate the long-term efficacy of an as-needed treatment with twice-daily applications…
The purpose of this study is to establish efficacy and safety of ligelizumab (QGE031) versus placebo in participants with chronic inducible urticaria who remain symptomatic despite treatment with H1 antihistamine.
Primary Objective: - Investigate whether recirculating tumor-associated tissue macrophages (TiMas), as well as circulating melanoma cells can be detected using high-end flow cytometry methods in peripheral blood from melanoma patients.Secondary…
Primary objective:To demonstrate superiority of Qutenza over low-dose capsaicin control in change from baseline to Week 12 in the 24-hr average pain intensity in subjects with PSNP.Secondary objective:• To demonstrate superiority of Qutenza over low…
Primair1. Assessment of the pharmacological activity of BAY·1834845 and BAY 1830839 on IMQ induced skin inflammation compared to placebo (prednisolone serves as active control), as quantified by laser speckle contrast imaging (LSCI, perfusion/basal…
The primary objective of the trial is to assess a non-flat dose-response curve and to evaluate the dose-response relationship for 3 oral dose regimens of BI 1291583 versus placebo, on the primary endpoint, time to first pulmonary exacerbation up to…
Primary objective: - To confirm the efficacy of twice-daily applications of delgocitinib cream 20 mg/g compared with cream vehicle in the treatment of adult subjects with moderate to severe CHE. Secondary objective: - To confirm the health-related…